financetom
Business
financetom
/
Business
/
PACCAR Q3 Net Income, Revenue Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PACCAR Q3 Net Income, Revenue Fall
Oct 21, 2025 5:52 AM

08:14 AM EDT, 10/21/2025 (MT Newswires) -- PACCAR ( PCAR ) reported Q3 net income Tuesday of $1.12 per diluted share, down from $1.85 a year earlier.

Analysts polled by FactSet expected $1.15.

Net sales and revenue for the quarter ended Sept. 30 were $6.67 billion, down from $8.24 billion a year earlier.

Analysts surveyed by FactSet expected $6.18 billion.

The company's shares were down more than 2% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Iris Energy Reports Higher Bitcoin Mining Output in September
Iris Energy Reports Higher Bitcoin Mining Output in September
Oct 4, 2024
09:26 AM EDT, 10/04/2024 (MT Newswires) -- Iris Energy ( IREN ) said Friday it mined 347 bitcoins in September, up from 245 in August. The company said its mining revenue in September was $21.4 million, up from $15 million in August, while its average operating hashrate increased to 16.5 exahash per second from 10.9 EH/s in August. Shares of...
Tellurian shareholders back proposed $1.2 billion Woodside deal
Tellurian shareholders back proposed $1.2 billion Woodside deal
Oct 4, 2024
(Reuters) - Tellurian shareholders have voted in favor of the U.S. LNG developer's proposed $1.2 billion acquisition by Australian energy producer Woodside Energy Group, the company said on Friday. Shares rose 1.4% to 98 cents in premarket trade. Woodside in July agreed to buy Tellurian, including its U.S. Gulf Coast Driftwood LNG export project. The agreement is expected help solve...
Johnson & Johnson discontinues dengue drug study
Johnson & Johnson discontinues dengue drug study
Oct 4, 2024
Oct 4 (Reuters) - Johnson & Johnson ( JNJ ) said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue. ...
J&J discontinues dengue drug study
J&J discontinues dengue drug study
Oct 4, 2024
(Reuters) -Johnson & Johnson ( JNJ ) said on Friday it will discontinue a mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue. The decision to discontinue the study was part of a reprioritization of the company's communicable diseases research and development portfolio, J&J said. In another mid-stage study, six of 10 participants...
Copyright 2023-2026 - www.financetom.com All Rights Reserved